AT
NBIX icon

American Trust’s Neurocrine Biosciences NBIX Stock Holding History

American Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,680
Closed -$353K – 308
2023
Q4 		$353K Sell
2,680
-370
-12% -$42.6K 0.03% 183
2023
Q3 		$343K Sell
3,050
-750
-20% -$79K 0.03% 196
2023
Q2 		$358K Sell
3,800
-120
-3% -$11.7K 0.02% 264
2023
Q1 		$397K Sell
3,920
-2,610
-40% -$272K 0.03% 249
2022
Q4 		$780K Buy
+6,530
New +$765K 0.07% 152

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

American Trust's NBIX Position: Q1 2024 in Review

American Trust sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 2,680 shares — an estimated $353K sold.

American Trust first reported a position in NBIX in Q4 2022 and held it in 5 quarters. The position peaked at $780K in Q4 2022. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • American Trust reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • American Trust sold 2,680 Neurocrine Biosciences shares in Q1 2024, an estimated $353K.
  • American Trust first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 5 quarters.
  • American Trust's Neurocrine Biosciences position peaked at $780K in Q4 2022.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on American Trust's 13F filing for Q1 2024, filed 11 Jun 2024.